Quotient Sciences Acquires Arcinova

Read the press release here

Arcinova continues rapid expansion with 30% increase in headcount

Arcinova has increased its headcount by 30% in the past 6 months. The recent influx of employees will enable Arcinova to be at the forefront of a digital manufacturing revolution for patient specific medicines.

Arcinova, a multi-service Contract Development and Manufacturing Organisation (CDMO), continues its rapid expansion with a 30% increase in headcount since January 2019. The 38 new employees have filled positions across Arcinova’s entire Alnwick site, including scientific, facilities and support services roles.

Since forming in February 2016, Arcinova has increased its workforce from around 50 to 135 people. It plans to continue growing at this rate, with the aim of recruiting a further 18 roles in the next six months and becoming a 300-strong workforce within the next three years. The majority of new recruits are recent graduates, with experience in working with state-of-the-art pharma technologies, including continuous flow manufacturing.

Arcinova’s growth coincides with the changing UK pharma landscape. There is now increased reliance on outsourcing and movement towards drug-discovery projects that target smaller patient groups. Arcinova has the expertise and technology in place to develop digital manufacturing platforms for small-molecule and high potency patient specific medicines, which will enable accelerated access to targeted drug therapy.

Gareth Jenkins, CSO at Arcinova, said: “As demand for our innovative drug development services grows, we are delighted to be expanding our team of talented scientists. Utilising the skills within the next generation of graduates will enable us to swiftly implement new technologies and be at the forefront of the personalised medicines revolution.”


Discover how Arcinova can help

We provide a fully integrated approach to drug development, speak to our team and discover how we can help you fast forward to market.